The IL10RB Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human non-small cell lung adenocarcinoma cell line NCI-H1975, engineered to disrupt the IL10RB gene. This product provides a loss-of-function model for investigating the biological roles of the interleukin-10 receptor subunit beta (IL10RB) in a lung cancer background, enabling studies of cytokine receptor signaling without reliance on pharmacological inhibition. The polyclonal nature of the knockout population preserves genetic heterogeneity, offering a robust platform for reproducible experimental outcomes in cancer biology and immunology research.
The NCI-H1975 parental cell line is an adherent epithelial cell line originally established from a 60-year-old female patient with non-small cell lung adenocarcinoma. It harbors activating mutations in the epidermal growth factor receptor (EGFR) gene??specifically, the L858R point mutation in exon 21 and the T790M gatekeeper mutation in exon 20??which drive constitutive kinase activity and oncogenic signaling, making it a well-characterized model for EGFR-targeted therapy resistance. NCI-H1975 cells are widely employed to study tumor cell proliferation, survival, and immune evasion mechanisms within the microenvironment of lung adenocarcinoma.
IL10RB encodes the interleukin-10 receptor beta chain, a shared subunit essential for signal transduction by the IL-10 family cytokines, including IL-10, IL-22, IL-26, and the type III interferons IFN-??1 (IL-29), IFN-??2 (IL-28A), and IFN-??3 (IL-28B). Upon ligand engagement, IL10RB heterodimerizes with ligand-specific alpha chains??such as IL10RA for IL-10, or IL20RA and IL22RA1 for IL-22 and IL-26 complexes??to recruit and activate the receptor-associated Janus kinases JAK1 and TYK2. These kinases directly phosphorylate the transcription factors STAT3 and, to a lesser extent, STAT1, which then dimerize and translocate to the nucleus to regulate the expression of downstream target genes including SOCS3, BCL2L1, CCND1, and MYC. Through this signaling cascade, IL10RB mediates anti-inflammatory and immune regulatory responses, as well as antiviral defense programs.
In the NCI-H1975 background, which harbors hyperactive EGFR signaling, IL10RB knockout offers a unique tool to dissect the interplay between oncogenic drivers and the tumor-regulating cytokine network. The IL-10/IL22/IFN-?? signaling axis, via IL10RB, may modulate cancer cell proliferation, apoptosis, and immune escape. Disruption of IL10RB enables the investigation of how these pathways influence EGFR inhibitor sensitivity and contribute to the acquisition of drug resistance, given the established role of STAT3 as a downstream effector shared by EGFR and cytokine receptors. This model also facilitates the study of IL10RB-dependent crosstalk with tumor-associated immune cells, providing insights into the immunomodulatory landscape of lung adenocarcinoma.
Researchers can utilize these polyclonal knockout cells in a variety of functional assays, including Western blot analysis of phospho-STAT3 and phospho-STAT1 to confirm disruption of downstream signaling, quantitative RT-PCR to measure changes in target gene expression such as SOCS3 and BCL2L1, and cytokine stimulation experiments with recombinant IL-10, IL-22, or IFN-?? ligands to assess receptor dependency. Flow cytometry can be employed to verify loss of IL10RB surface expression, while apoptosis and cell proliferation assays are suitable for evaluating functional consequences of IL10RB ablation in response to EGFR inhibitors or other therapeutic agents. Typical investigations include the examination of anti-inflammatory mechanisms, immune evasion strategies in non-small cell lung cancer, and the role of cytokine signaling in acquired drug resistance. For further details, including lot-specific validation data and customization options, please contact Ascent Research.
